{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"98.9","value":"329"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"407"}],"units":"Participants"}],"description":"Maximum serum concentration for atezolizumab.","dispersionType":"Standard Deviation","groups":[{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK)-evaluable population is defined as all patients who received any dose of study medication and who have at least one post-baseline PK sample available.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Cycle = 28 days)","title":"Maximum Serum Concentration (Cmax) for Atezolizumab","type":"SECONDARY","unitOfMeasure":"µg/mL"}